Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版

Ahead of print
Authors' Accepted
Current Issue
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us

Resources & Services

Email alert

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the

AJA Club (in English)
AJA Club (in Chinese)


Volume 10, Issue 4 (July 2008) 10, 525–534; 10.1111/j.1745-7262.2008.00409.x

Treatment of central precocious puberty by GnRH analogs: long-term outcome in men

Silvano Bertelloni1 and Dick Mul2

1 Adolescent Medicine, Department of Obstetrics, Gynecology and Pediatrics, Santa Chiara University Hospital, Pisa 56125, Italy
2 Leiden University Medical Center, Department of Paediatrics. PO Box 9600, 2300 RC Leiden, the Netherlands

Correspondence: Dr Silvano Bertelloni, Adolescent Medicine, Department of Obstetrics, Gynecology and Pediatrics, Santa Chiara University Hospital, Via Roma, 67, Pisa 56125, Italy. Fax: +39-050-888-622. E-mail: s.bertelloni@med.unipi.it

Received 7 January 2008; Accepted 30 January 2008


In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety. In the present paper, recent advances of CPP management with GnRH analogs in men are summarized. End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men. The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.

Keywords: adolescent, male, central precocious puberty, gonadotropin-releasing hormone analog treatment, gonadotropin-releasing hormone analog safety, long-term outcome, adult height

Full Text | PDF | 中文摘要 |

Browse:  7074
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.